Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

Stock Information for ProQR Therapeutics N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProQR Therapeutics N.V.

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
ProQR Announces First Quarter 2025 Operating and Financial Results
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
ProQR Announces Year End 2024 Operating and Financial Results
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.